• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

估算肾小球滤过率低是羟氯喹血药浓度升高的独立危险因素。

Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration.

机构信息

Department of Pharmacy, Peking University People's Hospital, Beijing, China.

Department of Rheumatology & Immunology, Peking University People's Hospital, No. 11 South Avenue, Xi Zhi Men, Xicheng District, Beijing, China.

出版信息

Clin Rheumatol. 2023 Jul;42(7):1943-1950. doi: 10.1007/s10067-023-06576-x. Epub 2023 Mar 20.

DOI:10.1007/s10067-023-06576-x
PMID:36939974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10267264/
Abstract

BACKGROUND

The aim of this study was to analyze the relationship of the estimated glomerular filtration rate (eGFR) to hydroxychloroquine (HCQ) blood concentrations in systemic lupus erythematosus (SLE) patients.

METHOD

Patients with SLE who had been taking HCQ for more than 12 months were recruited. All subjects gave written informed consent. Various clinical characteristics and laboratory values were examined. The blood concentration of HCQ was measured by high-performance liquid chromatography, and the relationship of eGFR to HCQ blood concentration was mainly investigated.

RESULT

In total, 115 patients with SLE receiving long-term HCQ therapy were included in the study. The median concentration of HCQ was 1096 ng/ml (range 116-8240 ng/ml). The eGFR was strongly associated with blood concentration of HCQ (P = 0.011, P < 0.05), when adjusted for age, sex, body mass index (BMI), weight-adjusted dose, prednisone use and immunosuppressive drug use. No statistically significant association were found between age, duration, BMI, weight-adjusted HCQ dose, corticosteroid use, immunosuppressant use and blood concentrations of HCQ.

CONCLUSION

We provided novel evidence that impaired renal function influenced the blood concentration of HCQ. Patients with low eGFR need to adjust the HCQ dosage according to the monitoring results of HCQ blood concentrations.

摘要

背景

本研究旨在分析系统性红斑狼疮(SLE)患者估算肾小球滤过率(eGFR)与羟氯喹(HCQ)血药浓度的关系。

方法

纳入长期服用 HCQ 超过 12 个月的 SLE 患者。所有受试者均签署书面知情同意书。检测各项临床特征和实验室指标。采用高效液相色谱法测定 HCQ 血药浓度,主要探讨 eGFR 与 HCQ 血药浓度的关系。

结果

共纳入 115 例长期接受 HCQ 治疗的 SLE 患者。HCQ 浓度中位数为 1096ng/ml(范围 116-8240ng/ml)。调整年龄、性别、体重指数(BMI)、体重校正剂量、泼尼松使用和免疫抑制剂使用后,eGFR 与 HCQ 血药浓度呈显著相关(P=0.011,P<0.05)。年龄、病程、BMI、体重校正 HCQ 剂量、皮质类固醇使用、免疫抑制剂使用与 HCQ 血药浓度之间无统计学显著相关性。

结论

本研究提供了新的证据,表明肾功能不全影响 HCQ 的血药浓度。eGFR 低的患者需要根据 HCQ 血药浓度监测结果调整 HCQ 剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0618/10267264/a6982abfe730/10067_2023_6576_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0618/10267264/aa4b8f5ad53c/10067_2023_6576_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0618/10267264/a6982abfe730/10067_2023_6576_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0618/10267264/aa4b8f5ad53c/10067_2023_6576_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0618/10267264/a6982abfe730/10067_2023_6576_Fig2_HTML.jpg

相似文献

1
Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration.估算肾小球滤过率低是羟氯喹血药浓度升高的独立危险因素。
Clin Rheumatol. 2023 Jul;42(7):1943-1950. doi: 10.1007/s10067-023-06576-x. Epub 2023 Mar 20.
2
Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.系统性红斑狼疮患者血液羟氯喹浓度的相关因素
Arthritis Care Res (Hoboken). 2017 Apr;69(4):536-542. doi: 10.1002/acr.22962. Epub 2017 Mar 7.
3
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.羟氯喹血药浓度在系统性红斑狼疮中的变化决定因素。
Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.
4
The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.肥胖对狼疮肾炎患者羟氯喹血药浓度的影响。
Lupus. 2021 Apr;30(4):554-559. doi: 10.1177/0961203320985214. Epub 2021 Jan 5.
5
Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.根据美国眼科学会指南调整羟氯喹剂量对系统性红斑狼疮的临床影响。
Lupus Sci Med. 2020 May;7(1). doi: 10.1136/lupus-2020-000395.
6
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.羟氯喹的日剂量、羟氯喹的血药浓度与系统性红斑狼疮患者病情恶化的风险。
Lupus Sci Med. 2023 Jan;10(1). doi: 10.1136/lupus-2022-000841.
7
Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.羟氯喹治疗狼疮孕妇可降低子痫前期风险。
Lupus. 2019 May;28(6):722-730. doi: 10.1177/0961203319843343. Epub 2019 Apr 10.
8
Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.羟氯喹在日本皮肤型或系统性红斑狼疮患者中的群体药代动力学
Ther Drug Monit. 2016 Apr;38(2):259-67. doi: 10.1097/FTD.0000000000000261.
9
Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.羟氯喹治疗系统性红斑狼疮患者的疗效和安全性取决于给药剂量。
Intern Med. 2020 Sep 1;59(17):2105-2112. doi: 10.2169/internalmedicine.4317-19. Epub 2020 Jun 9.
10
An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosus.一项旨在确定系统性红斑狼疮患者未使用羟氯喹的原因的观察性研究。
Sci Rep. 2024 Apr 2;14(1):7750. doi: 10.1038/s41598-024-58463-3.

引用本文的文献

1
Refining lupus management: a comprehensive review of HCQ blood levels.优化狼疮管理:对羟氯喹血液水平的全面综述
Rheumatol Adv Pract. 2025 Jul 7;9(3):rkaf080. doi: 10.1093/rap/rkaf080. eCollection 2025.
2
Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study.解读羟氯喹血药浓度以评估药物不依从性:一项药代动力学研究。
Lupus Sci Med. 2024 Apr 30;11(1):e001090. doi: 10.1136/lupus-2023-001090.
3
Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps.系统性红斑狼疮患者的治疗药物监测:效用与差距

本文引用的文献

1
The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus.亚太风湿病学协会联盟关于系统性红斑狼疮管理的共识声明
Lancet Rheumatol. 2021 Jul;3(7):e517-e531. doi: 10.1016/S2665-9913(21)00009-6. Epub 2021 Mar 25.
2
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
3
Update on antimalarials and systemic lupus erythematosus.
J Clin Med. 2024 Jan 13;13(2):451. doi: 10.3390/jcm13020451.
4
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.中国系统性红斑狼疮患者全血羟氯喹浓度的影响因素分析
Rheumatol Ther. 2023 Dec;10(6):1597-1607. doi: 10.1007/s40744-023-00598-2. Epub 2023 Sep 27.
抗疟药物与系统性红斑狼疮的最新进展。
Curr Opin Rheumatol. 2020 Nov;32(6):572-582. doi: 10.1097/BOR.0000000000000743.
4
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.2019 年更新版欧洲抗风湿病联盟与欧洲肾脏学会-欧洲透析和移植学会(EULAR/ERA-EDTA)狼疮肾炎管理建议。
Ann Rheum Dis. 2020 Jun;79(6):713-723. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.
5
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.羟氯喹血药浓度可预测羟氯喹视网膜病变。
Arthritis Rheumatol. 2020 Mar;72(3):448-453. doi: 10.1002/art.41121. Epub 2020 Jan 7.
6
Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.系统性红斑狼疮患者血液羟氯喹浓度的相关因素
Arthritis Care Res (Hoboken). 2017 Apr;69(4):536-542. doi: 10.1002/acr.22962. Epub 2017 Mar 7.
7
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).关于氯喹和羟氯喹视网膜病变筛查的建议(2016 年修订版)。
Ophthalmology. 2016 Jun;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16.
8
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.系统性红斑狼疮患者的羟氯喹血药浓度:阐明给药争议并提高依从性
J Rheumatol. 2015 Nov;42(11):2092-7. doi: 10.3899/jrheum.150379. Epub 2015 Oct 1.
9
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.羟氯喹血药浓度在系统性红斑狼疮中的变化决定因素。
Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.
10
The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.长期羟氯喹治疗患者中毒性视网膜病变的风险。
JAMA Ophthalmol. 2014 Dec;132(12):1453-60. doi: 10.1001/jamaophthalmol.2014.3459.